RATIONALE: There is limited data on the longitudinal growth parameters in pediatric patients with eosinophilic esophagitis (EoE). We analyzed the growth patterns and cortisol levels of EoE patients during long-term therapy. METHODS: Data from 146 pediatric patients with biopsy confirmed EoE who were prospectively enrolled into an observational database were analyzed. Long-term responders and non-responders were defined as less than or greater than 15 eosinophils/hpf for > _75% of their follow up time, respectively. First and last instance weight, height, and BMI (in percentiles) were analyzed. Cortisol levels were obtained as standard of care during endoscopy in patients on topical corticosteroid therapy (N565). RESULTS: The mean patient age was 7.23 years at study entry with an average follow up of 5.13 years. There was a significant difference between responder's and non-responder's initial BMI (38.10% and 51.82% respectively, p50.008) though by their final EGD this was no longer noted (44.82% and 53.32% respectively, p50.137). Baseline BMI differences were largely driven by older male children when the data were controlled for age and sex in a multivariable linear regression. The cortisol trajectory was not significantly different between responders and non-responders (-0.12 and -0.16 respectively, p50.503). CONCLUSIONS: Our study showed no significant difference in BMIs based upon therapeutic response to EoE treatment with non-responders having higher baseline BMIs and responders having catch-up in their BMIs to non-responders by the end of follow up. In this long-term study treatment with topical corticosteroids did not result in laboratory evidence of adrenal insufficiency.
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Investigation into specific IgE and IgG4 to the oligosaccharide galactose-a-1,3-galactose (aGal) in children with eosinophilic esophagitis RATIONALE: Serum specific IgE (sIgE) to food allergens are common in children with eosinophilic esophagitis (EoE), albeit usually at low titers, and we have recently reported that high-titer specific IgG4 (sIgG4) to milk proteins are also a feature of the disease. Foods, including dairy, are recognized as important triggers of EoE. The oligosaccharide galactose-a-1,3-galactose (a-Gal) is present in mammalian meat and dairy, is recognized in man as a foreign epitope and is the causal epitope in a syndrome of IgE-mediated delayed anaphylaxis. It is possible that a-Gal could be a relevant allergen that contributes to EoE pathogenesis. We sought to determine the prevalence and levels of IgE and IgG4 to a-Gal in children with EoE. METHODS: 15 children with EoE were enrolled from Nationwide children's (Columbus, OH) and 15 were enrolled from UVA Children's Hospital (Charlottesville, VA). Specific IgE and IgG4 to a-Gal were measured with ImmunoCAP as previously reported. RESULTS: sIgE to a-Gal was detected in 5 of 15 subjects from Central VA (33%) but no subjects from central OH, a finding that is consistent with the established distribution of the lone star tick. IgG4 titers to a-Gal were detectable in 29 of 30 subjects and ranged from 0.1-7.0 mg/mL. There was no association between a-Gal sIgE status and titers of a-Gal sIgG4. Interestingly, titers of sIgG4 to a-Gal trended higher in the children from Ohio. CONCLUSIONS: Here we show that IgG4 to a-Gal were common at low to moderate titer in children with EoE, but were not associated with IgE to a-Gal.
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The (EoE) is associated with various atopic disorders, but more information is needed to understand its complex association with food allergies, including those that elicit severe allergic reactions commonly caused by peanut allergy. The purpose of our study is to determine the prevalence of peanut allergy in patients diagnosed with EoE. METHODS: A retrospective chart review was conducted on EoE patients evaluated in the Eosinophilic Gastrointestinal Disorders Clinic at Texas Children's Hospital. Electronic medical records were reviewed from December 2012 to December 2017 on patients between the ages of 1 to 31 years with a diagnosis code of K20.0 to indicate EoE. Peanut allergy was confirmed from positive specific peanut IgE and/or prick skin testing, and a prior history of reaction following peanut ingestion. RESULTS: A total of 519 patients were identified and their records were reviewed. Of those patients, 159 (31%) were identified to have a peanut allergy. Overall there was a male predominance (3:1) for peanut allergy in EoE patients and a race distribution of 72% White, 16.4% African American, 15.7% Hispanic, and 7.5% Asian. 294 (57%) of EoE patients reported a food allergy to one of the top 8 food allergens. CONCLUSIONS: At our center, 1 out of 3 patients with a diagnosis of EoE had a concurrent diagnosis of peanut allergy which has implications for future therapeutic interventions. Patients with EoE should be screened for peanut allergies and appropriate recommendations should be provided to help prevent accidental exposures that could lead to life-threatening reactions.
